Avrion Therapeutics’ leadership reshuffle and R&D focus are outlined in a company update that previews strategic moves and pipeline priorities.
Key Takeaways
- Maximilien Murone was appointed interim CEO and previously led the company from 2020 to 2022
- Harald Petry will transition to Chairman of the Board and Chief Scientific Officer to guide R&D direction
- Avrion is advancing AVR-001 toward IND-enabling studies and developing AVR-002 as a targeted cytokine candidate